Hormonal
Adiponectin improves insulin sensitivity in skeletal muscle and liver by activating AMPK and PPAR-alpha pathways, leading to increased fatty acid oxidation and reduced hepatic glucose production.
While you cannot directly 'take' adiponectin as a simple supplement due to its complex structure and short half-life, the paper highlights that improving your metabolic health (e.g., through exercise and weight management) naturally optimizes your body's own adiponectin signaling. This signaling is crucial for how your muscles and liver handle energy, suggesting that lifestyle interventions that boost endogenous adiponectin are the most viable path to improving insulin sensitivity.
Adiponectin is a widely recognized insulin sensitizer... adiponectin administration increases fatty acid oxidation in skeletal muscle, and suppresses lipid accumulation in the liver by activating AMPK, thereby reducing triglyceride content in the liver and muscle and improving overall in vivo insulin sensitivity
Why this rating
The paper is a review of preclinical (mouse/cell) studies; human clinical data for therapeutic use is noted as lacking or challenging.
Source
Adiponectin signaling and function in insulin target tissues
Hong Ruan et al. · Journal of Molecular Cell Biology · 2016
DOI 10.1093/jmcb/mjw014
More from this paper
- Adiponectin enhances insulin signaling in target tissues by promoting the binding of IRS1/2 to the insulin receptor via the adaptor protein APPL1, thereby sensitizing cells to insulin.Moderate
- Adiponectin is not a viable direct therapeutic drug due to its high physiological concentration requirements, multiple oligomeric forms, and short half-life, but small-molecule activators like AdipoRon show promise.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →